Ecological association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007-2014

American Journal of Public Health

Volumn 106, Issue 12, 2016, Pages 2211-2218

  Flagg, Elaine W ^a   Torrone, Elizabeth A ^a   Weinstock, Hillard ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; FEMALE; HUMAN; INSURANCE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UNITED STATES; UTERINE CERVICAL DYSPLASIA; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UNITED STATES; UTERINE CERVICAL DYSPLASIA; VACCINATION; YOUNG ADULT;

EID: 84995665299     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2016.303472     Document Type: Article

References (54)

1. Centers for Disease Control and Prevention. United States Cancer Statistics (USCS) 1999-2013. Available at: http://www.cdc.gov/cancer/npcr/uscs/download- data.htm. Accessed July 26, 2016.
2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2(5):342-350.
3. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012; 30(suppl 5):F55-F70.
4. Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015; 107(6):djv086.
5. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
6. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):626-629.
7. Petrosky E, Bocchini JA, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300-304.
8. Reagan-Steiner S, Yankey D, Jayarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2014. MMWR Morb Mortal Wkly Rep. 2015; 64(29):784-792.
9. Williams WW, Lu P-J, O'Halloran A, et al. Vaccination coverage among adults, excluding influenza vaccination-United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(4):95-102.
10. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine. 2010;28(30): 4731-4737.
11. FUTURE I/II Study Group; Dillner J, Kjaer SK, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cer-vical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 341:c3493.
12. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19): 1928-1943.
13. Brotherton JM, Kaldor JM, Garland SM. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Sex Health. 2010;7(3):310-319.
14. Egelkrout EM, Galloway DA. The biology of genital human papillomaviruses. In: Holmes KK, Sparling PF, Stamm WE, et al., eds. Sexually Transmitted Diseases. 4th ed. New York, NY: McGraw Hill Medical; 2008: 463-487.
15. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5):731-738.
16. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001; 357(9271):1831-1836.
17. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005; 32(suppl 1):S16-S24.
18. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1157-1164.
19. Porras C, Rodriguez AC, Hildesheim A, et al. Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. Cancer Epidemiol Biomarkers Prev. 2009; 18(3):863-865.
20. Hariri S, Dunne E, Saraiya M, Unger E, Markowitz L.Human papillomavirus. In: Centers for Disease Control and Prevention, ed.Manual for the Surveillance of Vaccine-Preventable Diseases. Atlanta GA: Centers for Disease Control and Prevention; 2012.
21. Koutsky L. Epidemiology of genital human papil-lomavirus infection. Am J Med. 1997;102(5A):3-8.
22. Moscicki A-B. Impact of HPV infection in adolescent populations. J Adolesc Health. 2005;37(6 suppl):S3-S9.
23. Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev. 2011;20(2):287-296.
24. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis. 2012;16(3):175-204.
25. The American College of Obstetricians and Gyne-cologists. Committee on Practice Bulletins-Gynecology. Practice Bulletin no. 131. Screening for cervical cancer. Obstet Gynecol. 2012;120(5):1222-1238.
26. The American College of Obstetricians and Gyne-cologists. Committee on Practice Bulletins-Gynecology. Practice Bulletin no. 45. Cervical cytology screening. Obstet Gynecol. 2003;102(2):417-427.
27. The American College of Obstetricians and Gyne-cologists. Committee on Practice Bulletins-Gynecology. Practice Bulletin no. 109. Cervical cytology screening. Obstet Gynecol. 2009;114(6):1409-1420.
28. Moscicki A-B, Cox JT. Practice improvement in cervicalscreening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis. 2010;14(1): 73-80.
29. Wright TC, Massad S, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007;11(4): 201-222.
30. Wright TC, Massad S, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intra-epithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197(4):340-345.
31. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). 2006-2011. National Center for Health Statistics, Centers for Disease Control and Prevention. Available at: http://www.cdc. gov/nchs/icd/icd9cm.htm. Accessed July 28, 2016.
32. Healthcare Common Procedure Coding System (HCPCS) 2017-2014. Centers for Medicare and Medicaid Services. Encoder Pro, Optum 360. Accessed July 28, 2016.
33. Current Procedural Terminology-CPT® 2007-2014. American Medical Association. Encoder Pro, Optum 360. Accessed July 28, 2016.
34. Flagg EW, Torrone EA. Utility of International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes for evaluating population impact of human papillomavirus (HPV) vaccination on high-grade cervical intraepithelial lesions using healthcare claims data. 2015. Available at: http://www.cdc.gov/nchs/events/2015nchs/poster-abstracts.htm#posterIII. Accessed September 2, 2015.
35. Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data. Am J Epidemiol. 2010; 171(5):618-623.
36. National Cancer Institute. Surveillance research. SEER∗Stat Software. Trend algorithms. Percent change. Available at: http://seer.cancer.gov/seerstat/WebHelp/seerstat.htm#Statistics-Calculated-by-SEER-Stat.htm. Accessed May 19, 2015.
37. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Per-mutation tests for joinpoint regression with applications to cancer rates [erratum in Stat Med. 2001;20:655]. Stat Med. 2000;19(3):335-351.
38. National Cancer Institute. Surveillance research. Joinpoint. Getting help. Joinpoint online help system. Joinpoint User's Guide 4.2. Average annual percent change. Available at: http://surveillance.cancer.gov/joinpoint/help.html. Accessed May 19, 2015.
39. Centers for Disease Control and Prevention. Vaccination coverage among adolescents aged 13-17 years-United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(40): 1100-1103.
40. Taylor LD, Hariri S, Sternberg M, Dunne EF, Markowitz LE. Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007-2008. Prev Med. 2011;52: 398-400.
41. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-314.
42. Winer RL, Feng Q, Hughes JP, O' Reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis. 2008;197(2):279-282.
43. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health. 2013;103(8): 1428-1435.
44. Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):e20151968.
45. Hariri S, Bennett NM, Niccolai LM, et al. Reductionin HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States-2008-2012. Vaccine. 2015;33(13):1608-1613.
46. Brotherton JML, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783): 2085-2092.
47. Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control. 2014;25(7): 915-922.
48. Mahmud SM, Kliewer EV, Lambert P, Bozat-Emre S, Demers AA. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. J Clin Oncol. 2014;32(5):438-443.
49. Pollock KG, Kavanagh K, Potts A, et al. Reduction of low-and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111(9):1824-1830.
50. Ranji U, Salganicoff A, Stewart AM, Cox M, Doamekpor L. State Medicaid coverage of family planning services. Summary of state survey findings. Kaiser Family Foundation. 2009. Available at: http://kff.org/medicaid/state-medicaid-coverage-of-family-planning-services. Accessed July 27, 2016.
51. Gates A, Ranji U, Snyder L. Coverage of preventive services for adults in Medicaid. Issue Brief. Kaiser Family Foundation. 2014. Available at: http://kff.org/medicaid/issue-brief/coverage-of-preventive-services-for-adults-in-medicaid. Accessed July 27, 2016.
52. National Breast and Cervical Cancer Early Detection Program. About the program. Available at: http://www. cdc.gov/cancer/nbccedp/about.htm. Accessed July 27, 2016.
53. Kaiser Family Foundation. The HPV vaccine: access and use in the U.S. 2015. Available at: http://kff.org/womens-health-policy/fact-sheet/the-hpv-vaccine-access-and-use-in. Accessed July 29, 2016.
54. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Parakevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367(9509):489-498.